EUVIMEDEUVIMED entdecken
Crossref

L26/P-727 Bone health in transgender women: effects of gender-affirming hormone therapy

F. Widemair, S. Stefanie, B. Toth, K. Feil

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von F. Widemair und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question The aim of our study was to analyze bone health in trans women and the effects of GAHT on over a five-year observation period. Summary answer Bone mineral density in trans women partially improved after five years of GAHT, showed no decline, and reached levels comparable to young cisgender women. What is known already Gender-affirming hormone therapy (GAHT) represents a medical intervention for transgender and gender-diverse (TGD) individuals to alleviate distress associated with gender dysphoria and affirm their experienced gender. In general, GAHT in trans women assigned male at birth aims to align serum hormone levels with the affirmed gender through estradiol administration and testosterone suppression. In adulthood, estrogens are essential for maintaining bone mineral density and trabecular bone mineral content through their regulatory effects on osteoclast and osteoblast activity. Consequently, due to the bone-physiological effects of sex hormones, bone health monitoring by dual-energy X-ray absorptiometry (DEXA) every five years during GAHT is recommendend. Study design, size, duration This study is a single-center longitudinal study based on retrospectively collected data from 2003-xx. A total of 113 trans women who had completed baseline assessments were included in the study. Complete five-year GAHT follow-up data were available for 20 participants. GAHT-naive transgender women underwent dual-energy X-ray absorptiometry and corresponding laboratory assessments at study baseline and after five years of GAHT, including hormonal parameters and markers of bone metabolism. Participants/materials, setting, methods Trans women who had undergone gender-affirming hormonal suppression therapy with GnRH agonists (GnRHa) or cyproterone acetate in combination with GAHT were included. Patients were excluded if they had not received GAHT and GnRHa, or if the duration of therapy was less than six months. Statistical analyses were performed using the Wilcoxon signed-rank test for paired samples, with the level of significance set at 0.05. Main results and the role of chance Mean baseline estradiol (E2) levels were 58.62 ± 84.8 ng/L (vs. 159.89 ± 165.4 ng/L after five years), mean luteinizing hormone (LH) levels 3.68 ± 3.11 U/L (vs. 9.85 ± 18,37 U/L after 5 years), calcium 2.37 ± 0.12 mmol/L (vs. 2.34 ± 0.12 mmol/L after 5 years), phosphate 1.03 ± 0.22 mg/dL (vs. 0.85 ± 0.16 mg/dl after five years) and bone-specific alkaline phosphatase (BAP) 85.3 ± 32,9 U/L (vs. 59.13 ± 12,97 U/L after five years). Baseline BMD was 0.967 ± 0.13 g/cm² at the lumbar spine, 0.833 ± 0.129 g/cm² at the femoral neck, and 0.943 ± 0.127 g/cm² at the total proximal femur. Mean baseline assigned Z-scores were −0.508 ± 1.2, −0.675 ± 1.13 and −0.372 ± 0.989. After five years of GAHT, mean values increased to 159.89 ± 165.4 ng/L for E2 and 9.85 ± 18,37 U/L for LH and a significant improvement in lumbar BMD was observed (0.967 g/cm² vs. 1.016 g/cm²; p = 0.011). Likewise, lumbar bone mineral content increased significantly from 63.323 g to 70.541 g (p = 0.023). The femoral neck Z-score, adjusted for the female reference, also improved significantly from −0.675 to 0.013 after five years of GAHT (p = 0.042). Limitations, reasons for caution In this study, only Z-scores based on the participants’ affirmed gender were used, while some differences are seen when using reference values for their sex assigned at birth. Wider implications of the findings Bone mineral density in trans women partially improved after five years of GAHT compared with baseline. None of the values showed any decline. After completion of the five-year GAHT period, participants’ values were within the range observed in young cis female and were therefore comparable. Trial registration number No

Zitieren

APA

Widemair, F., Stefanie, S., Toth, B., & Feil, K. (2026). L26/P-727 Bone health in transgender women: effects of gender-affirming hormone therapy. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1054

Vancouver

Widemair F, Stefanie S, Toth B, Feil K. L26/P-727 Bone health in transgender women: effects of gender-affirming hormone therapy. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1054

BibTeX
@article{Widemair2026,
  author = {Widemair, F. and Stefanie, S. and Toth, B. and Feil, K.},
  title = {L26/P-727 Bone health in transgender women: effects of gender-affirming hormone therapy},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1054}
}
Kostenlos starten →